Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)    
$116.97 3.31 (2.75%) as of 4:30 Mon 4/27


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 148,000,000 as of 9/30
Market Cap: 17.31(B)
Last Volume: 2,546,302 Avg Vol: 1,253,554
52 Week Range: $56.17 - $129.135
Level I Sector: Health Care
Level II Sector:   Drugs
Level III Sector:      Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY       NASDAQ COMPOSITE  
    NASDAQ NNM COMPOSITE  

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
 

Company Profile   BioMarin Pharmaceutical develops and commercializes pharmaceuticals. Co.'s approved products include: Naglazyme (galsulfase) for patients with mucopolysaccharidosis VI; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Aldurazyme (laronidase) for patients with mucopolysaccharidosis I; and Firdapse (amifampridine phosphate) for the treatment of Lambert Eaton Myasthenic Syndrome. Co. is also conducting clinical trials on several investigational product candidates including, among others: Vimizim™, for the treatment of mucopolysaccharidosis Type IV or Morquio Syndrome Type A; and PEG-PAL for the treatment of phenylketonuria.

 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 209,855 394,177 469,517 983,587
Total Sell Value $24,116,716 $39,872,156 $44,867,108 $80,542,257
Total People Sold 7 9 10 12
Total Sell Transactions 19 38 63 124
End Date 2015-01-25 2014-10-24 2014-04-25 2013-04-25

   
Records found: 1354
  Page 1 of 55  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-04-01 4 OE $6.46 $145,647 I/I 22,546 55,804     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-04-01 4 AS $120.53 $2,717,546 I/I (22,546) 33,258 -1%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-04-01 4 AS $120.53 $422,590 D/D (3,506) 251,251 -1%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-20 4 AS $126.40 $126,396 I/I (1,000) 33,258 -4%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-17 4 AS $124.87 $124,866 I/I (1,000) 34,258 -5%     
   Mueller Brian VP, Corporate Controller   •       –      –    2015-03-16 4 A $0.00 $0 D/D 4,000 12,800     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2015-03-16 4 OE $21.51 $860,400 D/D 40,000 129,950     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2015-03-16 4 AS $123.57 $5,105,166 D/D (41,315) 88,635 -3%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-16 4 AS $123.48 $123,477 I/I (1,000) 35,258 -3%     
   Davis George Eric SVP, General Counsel   •       –      –    2015-03-13 4 OE $26.49 $556,239 D/D 15,000 88,846     -
   Davis George Eric SVP, General Counsel   •       –      –    2015-03-13 4 S $120.87 $1,813,002 D/D (15,000) 73,846 3%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-10 4 S $114.89 $232,201 I/I (2,021) 36,258 -5%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-09 4 OE $12.99 $194,850 I/I 15,000 57,279     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-09 4 S $112.12 $2,130,383 I/I (19,000) 38,279 -6%     
   Baffi Robert EVP, Technical Operations   •       –      –    2015-03-05 4 OE $14.39 $240,364 D/D 14,051 123,751     -
   Baffi Robert EVP, Technical Operations   •       –      –    2015-03-05 4 S $116.37 $1,635,091 D/D (14,051) 109,700 -6%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-05 4 OE $12.99 $129,900 I/I 10,000 52,279     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-05 4 S $113.70 $1,137,016 I/I (10,000) 42,279 -6%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-04 4 OE $9.86 $4,930 I/I 500 43,695     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-04 4 AS $107.71 $98,660 I/I (916) 42,279 6%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-03 4 AS $107.42 $537,097 D/D (5,000) 215,157 6%     
   Mueller Brian VP, Corporate Controller   •       –      –    2015-03-03 4 OE $28.23 $197,610 D/D 7,000 15,800     -
   Mueller Brian VP, Corporate Controller   •       –      –    2015-03-03 4 S $109.46 $766,210 D/D (7,000) 8,800 -6%     
   Lapalme Pierre Director   –       •      –    2015-03-03 4 OE $11.15 $284,800 D/D 20,000 50,150     -
   Lapalme Pierre Director   –       •      –    2015-03-03 4 S $106.57 $2,131,400 D/D (20,000) 30,150 -6%     

  1354 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 55
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed